Follow-up studies on preterm infants after maternal beta-receptor agonist treatment.

A review of the existing literature regarding the outcome of infants delivered preterm after antenatal beta-receptor agonist treatment of the mother is presented. Some investigators have reported an increased rate of neonatal and long-term hazards, while others have not found a higher incidence of such complications after antenatal beta-receptor treatment. In our own material of 55 preterm survivors with follow-up up to 2 years of age, we found a modest rise in postnatal hypoglycemia rate but no other short-term or long-term sequelae. Postnatal monitoring of blood glucose and cardiovascular function is warranted at preterm deliveries after antenatal beta-receptor agonist treatment.